Trials / Recruiting
RecruitingNCT06929663
A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 for Injection, an Anti-Trop2/Nectin4 Bispecific Antibody-drug Conjugate, in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK146D1 for injection | AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate |
Timeline
- Start date
- 2025-07-02
- Primary completion
- 2026-11-05
- Completion
- 2027-05-05
- First posted
- 2025-04-16
- Last updated
- 2025-07-17
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06929663. Inclusion in this directory is not an endorsement.